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Objectives:Nevirapine is widely used for the treatment of HIV-1 infection; however, its chronic use has been asso-
ciatedwith severe liver and skin toxicity.Womenare at increased risk for these toxic events, but the reasons for the
sex-related differences are unclear. Disparities in the biotransformation of nevirapine and the generation of toxic
metabolites between men and women might be the underlying cause. The present work aimed to explore sex
differences in nevirapine biotransformation as a potential factor in nevirapine-induced toxicity.
Methods: All included subjects were adults who had been receiving 400 mg of nevirapine once daily for at least
1 month. Blood samples were collected and the levels of nevirapine and its phase I metabolites were quantified
byHPLC.Anthropometric andclinical data, andnevirapinemetaboliteprofiles,wereassessed for sex-relateddiffer-
ences.
Results: A total of 52 patients were included (63% were men). Body weight was lower in women (P¼0.028)
and female sex was associated with higher alkaline phosphatase (P¼0.036) and lactate dehydrogenase
(P¼0.037) levels. The plasma concentrations of nevirapine (P¼0.030) and the metabolite 3-hydroxy-nevirapine
(P¼0.035), as well as the proportions of the metabolites 12-hydroxy-nevirapine (P¼0.037) and 3-hydroxy-
nevirapine (P¼0.001), were higher in women, when adjusted for body weight.
Conclusions: There was a sex-dependent variation in nevirapine biotransformation, particularly in the generation
of the 12-hydroxy-nevirapine and 3-hydroxy-nevirapine metabolites. These data are consistent with the sex-
dependent formation of toxic reactive metabolites, which may contribute to the sex-dependent dimorphic profile
of nevirapine toxicity.
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Introduction
The availability of combined antiretroviral therapy (cART) has
changed the prognosis of HIV infection in properly medicated
patients from a lethal disease into a chronic condition. However,
HIV-positive individuals still face obstacles associatedwith chronic
cARTuse, particularly related to long-term adverse events.1
Nevirapine was the first approved non-nucleoside reverse tran-
scriptase inhibitor (NNRTI),2 and is still the most prescribed drug
among this class. It is also themost used antiretroviral in countries
with limited economic resources, particularly due to its low cost.3
One of the most relevant benefits of nevirapine is its efficacy in
the prevention of mother-to-child HIV transmission, with the
drug being commonly indicated for pregnant women and their
children.3–6
Despite its clinical efficacy, nevirapine is associated with hep-
atotoxicity and skin rash. These reactionsmay lead to drug discon-
tinuation or even be fatal.5,7–9 Moreover, nevirapine can induce
hepatocellular neoplasias in animal models,10 and recent epi-
demiological data suggest an association between chronic NNRTI
use and an increased incidence of non-AIDS-defining cancers in
HIV-1-infected patients.1
Although the mechanisms underlying nevirapine toxicity are
still not fully understood, the current evidence is strongly consist-
entwith a higher risk inwomen11–13and a subjacent immuneme-
diation.9,14–16Toallowfor sexdifferences in immunehyper-reactivity,
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it is recommended that in cART-naive women nevirapine should be
initiated only in those with a CD4+ cell count ,250 cells/mm3,
whereas in men this cut-off is 400 cells/mm3.17
The attempts to correlate nevirapine exposure and toxicity out-
comes have so far been inconclusive,18–22 which suggests that
nevirapine biotransformation to reactive metabolites, rather than
the levels of the parent drug, may be the basis of the drug’s
adverse effects. In humans, nevirapine biotransformation involves
the generation of several hydroxylated phase I metabolites (at
nevirapine positions 2, 3, 8 and 12; Figure 1).23,24 Whether or not
and how these metabolites promote hypersensitivity reactions is
unknown, but protein haptenation might be involved. In fact,
upon bioactivation, these metabolites may generate electrophilic
species25,26capableofbindingcovalently toproteinsandotherbio-
macromolecules (Figure 1).25–32The involvement of phase II reac-
tions, and particularly the sulphotransferase (SULT)-mediated
formation of 12-sulphoxy-nevirapine from12-hydroxy-nevirapine,
has recently gained increased support as a major player in this
context,25,27,29–32 with protein adducts from this pathway hav-
ing already been detected in patients on therapeutic doses of
nevirapine.28,29
These new insights into the implications of nevirapine biotrans-
formation highlight the importance of exploring sex-related varia-
tions in the formationof toxic nevirapinemetabolites, whichmight
explain the higher risk for nevirapine toxicity in women. The aim of
the currentworkwas to investigate sexdifferences in phase I nevir-
apine biotransformation in HIV-infected patients.
Patients and methods
Patient inclusion, data gathering and blood sampling
The currentworkwas conducted in accordancewith theDeclaration of Hel-
sinki. Thestudyprotocol receivedpriorapproval fromtheEthicsCommittees
of Centro Hospitalar de Lisboa Central, EPE (process number 32-CHLC) and
Hospital Prof. Doutor Fernando Fonseca, EPE (process number CA21/2011),
and was also approved by the National Committee for Data Protection
(process number 6567/2009). The patients gave their written informed
consent and adherence was controlled by the clinician. All patients were
adults with documented HIV infection who had been using nevirapine-
containing cART (400 mg once daily) for at least 1 month, regardless of
the past therapeutic history. Exclusion criteria were being ,18 years of
age, havingAIDS-defining conditions, andcompliance issues. The following
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Figure 1. Nevirapine biotransformation, disposition and proposed bioactivation pathways. Nevirapine (NVP) is metabolized by several isoforms of
cytochrome P450 (CYP), yielding several phase I metabolites: 2-hydroxy-nevirapine (2-OH-NVP), 3-hydroxy-nevirapine (3-OH-NVP), 8-hydroxy-nevirapine
(8-OH-NVP) and 12-hydroxy-nevirapine (12-OH-NVP).24 12-OH-NVP is further oxidized by CYP450 to yield 4-carboxy-nevirapine (4-COOH-NVP).25 The
phase I nevirapine metabolites undergo extensive glucuronidation via UDP-glucuronosyltransferase (UGT), which represents a major pathway of
nevirapine elimination.24 The bioactivation of 12-OH-NVP by SULTs can generate 12-sulphoxy-nevirapine (12-sulphoxy-NVP), a reactive metabolite that
binds covalently to proteins and DNA.28,29,53 The formation of DNA adducts could explain the increased incidence of non-AIDS-defining cancers among
HIV-infected patients treated with NNRTIs.1 Also, the formation of adducts with proteins could explain the nevirapine-associated adverse reactions,
hepatotoxicity and skin rash.15 The presence of glutathione (GSH) adducts and mercapturates in patients and animal models treated with nevirapine
has also been detected.26
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datawere gathered for each patient: age, ethnicity, weight, height, time on
nevirapine, time between last nevirapine intake and blood sampling, viral
load, CD4+ cell count and hepatic function biomarkers [alanine amino-
transferase (ALT), lactate dehydrogenase (LDH), gamma-glutamyltransferase
(GGT), alkaline phosphatase (ALKP) and bilirubin]. Blood samples (2 mL) were
collected into EDTA-containing tubes.
Extraction of analytes from blood samples and HPLC
quantification
Plasma was obtained by centrifugation of blood at 3000 g for 10 min.
Aliquots of the plasma (900 mL) were heated at 608C for 60 min for viral in-
activation before handling at room temperature.
Pirenzepine was purchased from Sigma–Aldrich (Madrid, Spain) and
used as an internal standard. Analytes were then extracted from plasma
with dichloromethane (VWR, Radnor, PA, USA).
Nevirapine was obtained from Cipla (Maharashtra, India) and the
2-hydroxy, 3-hydroxy-, 8-hydroxy- and 12-hydroxy-nevirapine metboli-
tes were synthesized as described previously33,34 and used as standards
for HPLC quantification.
HPLCanalysesof thenevirapineandmetaboliteprofilewereconductedon
an Agilent 1100 Series system (Agilent Technologies, Santa Clara, CA, USA)
using a reversed-phase Luna C18 (2) column (250 mm×4.6 mm; 5mm; Phe-
nomenex, Torrance, CA, USA). The mobile phase—10% acetonitrile (VWR) in
15 mM ammonium acetate (Merck, Darmstadt, Germany) buffer, pH 4—
was delivered at a flow rate of 0.8 mL/min for 90 min; the flow rate was
then increased to 1.5 mL/min over 5 min and maintained at this value for
an additional period of 19min. The column temperaturewas 408C, the injec-
tion volumewas 100 mL and UVabsorbance was monitored at 254 nm. The
lower limit of quantification of themethod was 10 ng/mL for each analyte.
Statistical analyses
Systemic exposure to the different nevirapine metabolites was assessed in
terms of absolute concentrations and as the proportion of eachmetabolite
in the plasma. Mean (+SEM), median (IQR) number and percentage were
used to describe the study population. Student’s t-test was performed for
comparisonsbetweenmeansandtheMann–WhitneyU-testwasperformed
for comparisons betweenmedians. The statistical analyses were performed
using Graph Prismw 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Results
A total of 52 patients (63% men) were included in the study. The
anthropometric and clinical data are presented in Table 1.
Body weight was significantly higher in men compared with
women, but the body mass index was similar in the two groups.
Among the liver function tests analysed, differences were found
for LDH and ALKP, which were higher in women.
Therewerenodifferencesbetweensexes regardingage, timeon
nevirapine, time between sampling and last nevirapine intake, CD4
cell counts, ALT, GGTand direct bilirubin; the total bilirubin concen-
tration was higher in men (Table 1). All patients had an undetect-
able viral load.
Sexdifferences in theplasmaconcentrationofnevirapineand in
its metabolite profile are presented in Table 2. Women had higher
nevirapine and 3-hydroxy-nevirapine plasma concentrations,
whenadjustedforbodyweight.Allpatientshad8-hydroxy-nevirapine
levels below the lower limit of quantification of our method.
Sex differences in the proportions of nevirapinemetabolites are
presented in Table 3. Women had a significantly higher proportion
of 12-hydroxy-nevirapine and 3-hydroxy-nevirapine compared
with men, when the data were adjusted for body weight.
Discussion
Nevirapine is a remarkable example of a drug with a sexually di-
morphic profile of adverse drug reactions, with women being at
greater risk of experiencing skin and liver toxicity. It has recently
been hypothesized that nevirapine biotransformation plays an im-
portant role in the onset of these adverse effects.35 However, sex-
dependent differences in nevirapine pharmacokinetics have been
Table 1. Anthropometric and clinical data
Parameter Men Women P value
Number of patients 33 19
Percentage of non-Caucasians 42 32
Age (years)a 50 (39–60) 46 (38–63) NS
Body weight (kg)b 73+2 65+3 0.028
Body mass index (kg/m2)b 25+1 25+1 NS
Time on nevirapine (years)a 4 (2–9) 4 (2–7) NS
Time between sampling and last nevirapine intake (h)a 12 (6–15) 13 (11–15) NS
CD4+ cell count (cells/mm3)a 515 (386–675) 575 (413–735) NS
ALT (U/L)a 36 (23–47) 31 (26–45) NS
ALKP (U/L)a 80 (69–106) 110 (82–155) 0.036
LDH (U/L)a 181 (167–243) 228 (196–244) 0.037
GGT (U/L)a 70 (36–134) 59 (51–126) NS
Total bilirubin (mg/dL)a,c 0.39 (0.33–0.47) (n¼25) 0.33 (0.27–0.40) (n¼15) 0.026
Direct bilirubin (mg/dL)a,c 0.1 (0.08–0.11) (n¼17) 0.1 (0.07–0.11) (n¼13) NS
NS, not significant.
Differences were considered significant if P, 0.05.
aMann–Whitney U-test, median (IQR).
bStudent’s t-test, mean+SEM.
cMissing values correspond to patients for whom clinical data were not available.
Sex differences in nevirapine pharmacokinetics
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poorly explored. In the present work, sex differences in the
biotransformation profile of nevirapine were studied in order to
explore their potential role in nevirapine toxicity. We found that
the nevirapine phase I metabolite profile was dissimilar between
men and women, with differences being most noteworthy for
the 12-hydroxy-nevirapine and 3-hydroxy-nevirapine metabolites,
which had higher plasma levels in women.
Pharmacokinetic variation has been implicated as the main
factor underlying the increased rate and wider range of drug-
induced toxicity reactions in women.36,37 These effects have
often been purported to be related to higher drug bioavailability
in females.36–40 These pharmacokinetic differences may arise
due to variations in endogenous and exogenous hormones, and
also in livermetabolism.36Moreover, bodysizeand fat composition
are also thought to contribute. Females typically havea lower body
weight and size thanmales, and also a higher percentage of body
fat, whichmight influence the distribution volume of drugs, in par-
ticular those that are highly lipophilic, such as nevirapine.37
In fact, a relationship between lower body weight, lower
nevirapine clearance and higher nevirapine toxicity has been
described.41–43 However, the attempts to demonstrate that
patients experiencing higher plasma nevirapine levels are at
greater risk for nevirapine toxicity have failed, as divergent results
have been obtained.16,18,20–22,44–47 Nonetheless, it is important
to highlight that body weight adjustment was rarely performed
in these studies.20–22,44,45
As expected, in our study population women had lower body
weights thanmen. Additionally, the sex differences found in nevir-
apine biotransformation weremore pronouncedwhen normaliza-
tion per unit bodyweightwas performed. This excludes lower body
weight as the only factor explaining the different nevirapine bio-
transformation between the sexes. The absence of a correlation
between nevirapine concentration and toxicity20–22,45 might
suggest that nevirapineper se is not toxic, but can form toxicmeta-
bolites upon biotransformation.48
Nevirapine is biotransformed into several hydroxylated meta-
bolites via phase I cytochrome P450mediation (Figure 1). Females
havehigherCYP3A4,2A6and2B6activities,while sexdifferences in
CYP2C9 and 2D6 have not been described.37,49,50 Moreover, evi-
dence obtained from pharmacogenetic data has suggested an in-
fluence of CYP2C19 on nevirapine plasma levels,51 although
without specifying the particular metabolite(s) generated. This
CYP isoenzyme has also been linked to the generation of reactive
metabolites capable of binding to glutathione and forming nevi-
rapine–glutathione adducts in vitro.31 Recently, the involvement
of CYP2C19 in the formation of 12-hydroxy-nevirapine was ex-
cluded,52 but its influence in the generation of the other phase I
metabolites was not assessed. The reported higher CYP3A4, 2A6
and2B6activities in females are consistentwith thehigher propor-
tions of 12-hydroxy-nevirapine and 3-hydroxy-nevirapine found
for women in the current work (Figure 1 and Tables 2 and 3).
PreviousworkbyHall andMacGregor22didnot identifyanystrong
correlation between plasma levels of nevirapine or itsmajor phase I
metabolites and either hepatotoxicityor skin rash events, or sex dif-
ferences inmetaboliteproportions.Nevertheless,noadjustmentper
unitofbodyweightwasperformed in that study.Also, it is important
tohighlight thattheauthorsperformedanextractionoftheanalytes
Table 2. Plasma concentrations of nevirapine and its phase I metabolites
Men (n¼33) Women (n¼19) P value
Analyte (ng/mL)
NVPa 4279 (2678–5105) 4233 (3533–5130) NS
2-OH-NVPa,b 58.6 (29.5–109.6) (n¼19) 63.2 (31.3–80.5) (n¼7) NS
3-OH-NVPa,b 24.0 (17.2–31.3) (n¼31) 33.7 (22.7–38.6) (n¼17) 0.047
12-OH-NVPa 364.9 (247.3–543.4) 371.0 (270.2–450.7) NS
Analyte (ng/mL/kg)
NVPa 53.9 (34.6–72.9) 70.7 (51.8–86.4) 0.030
2-OH-NVPa,b 0.73 (0.42–1.78) (n¼19) 0.92 (0.34–1.73) (n¼7) NS
3-OH-NVPa,b 0.34 (0.23–0.47) (n¼31) 0.52 (0.32–0.73) (n¼17) 0.035
12-OH-NVPa 4.80 (3.48–8.47) 6.06 (3.87–7.79) NS
NS, not significant; NVP, nevirapine; 2-OH-NVP, 2-hydroxy-nevirapine; 3-OH-NVP, 3-hydroxy-nevirapine; 12-OH-NVP, 12-hydroxy-nevirapine.
Differences were considered significant if P,0.05.
aMann–Whitney U-test, median (IQR).
bMissing values correspond to patients for whom the metabolite concentration was below the lower limit of quantification for the method.
Table 3. Sex differences in the proportions of the major nevirapine phase I
metabolites
Men (n¼33) Women (n¼19) P value
%
2-OH-NVPa 11.1 (8.2–18.5) 9.6 (7.8–21.9) NS
3-OH-NVPb 5.5+0.4 7.5+0.8 0.013
12-OH-NVPa 88.2 (79.8–94.7) 90.8 (83.2–93.8) NS
%/kg
2-OH-NVPa 0.17 (0.11–0.26) 0.15 (0.08–0.42) NS
3-OH-NVPb 0.08+0.01 0.12+0.02 0.001
12-OH-NVPa 1.24 (1.04–1.29) 1.35 (1.17–1.76) 0.037
NS, not significant; 2-OH-NVP, 2-hydroxy-nevirapine; 3-OH-NVP,
3-hydroxy-nevirapine; 12-OH-NVP, 12-hydroxy-nevirapine.
Differences were considered significant if P,0.05.
aMann–Whitney U-test, median (IQR).
bStudent’s t-test, mean+SEM.
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precededbyaglucuronidase treatment step. This step precludedan
estimation of the levels of free phase Imetabolites, which prevents
direct comparison with our data.
The formationofglucuronides (Figure1) isamajor routeofelim-
ination of nevirapine phase I metabolites.24 However, the involve-
ment of phase II metabolic pathways, namely sulphonation,
cannot be excluded.48 For instance, the bioactivation of 12-hydroxy-
nevirapine by SULTs has been increasingly indicated as the plaus-
ible mechanism for nevirapine-associated toxicity.25–30,32,48
12-Hydroxy-nevirapine is a non-reactive metabolite per se;
however, it can be bioactivated by SULTs in the liver and skin, yield-
ing the reactive species 12-sulphoxy-nevirapine.32Moreover, using
12-mesyloxy-nevirapine as a synthetic surrogate for 12-sulphoxy-
nevirapine, we have shown covalent binding of this reactive elec-
trophile in vitro to several amino acids,27 haemoglobin and human
serum albumin,30 as well as nucleosides and DNA.53,54 We have
also demonstrated for the first time the presence of 12-hydroxy-
nevirapine-derived haemoglobin adducts in HIV-infected patients.28
More recently, Sharma et al.32 showed covalent binding of 12-
sulphoxy-nevirapine to skin proteins after incubation of this react-
ive metabolite with skin homogenate. Likewise, recent work by
Meng et al.29 showed evidence for the formation of nevirapine–
human serum albumin adducts, consistent with reaction with
12-sulphoxy-nevirapine. Nevertheless, the detection of 12-sulphoxy-
nevirapine inman has not yet been achieved.
Recentevidencehas shownthat recombinanthumanSULT1A1*1
is capable of converting 12-hydroxy-nevirapine into 12-sulphoxy-
nevirapine.32 Owing to its broad spectrum of substrates and high
hepatic and extrahepatic expression, SULT1A1 appears to be the
main form of human SULT involved in the detoxification of xenobio-
tics, particularlyphenolicmetabolites.55Nonetheless, furtherstudies
areneeded to clarifywhetherother SULTsplaya role in thebioactiva-
tion of 12-hydroxy-nevirapine56 (Figure 1), as well as whether the
isoforms involved are the same in skin and liver.
It is known that SULT1A1 is highly polymorphic and that there
are marked differences in the activities of SULT1A1 variants
(1A1*1, 1A1*2and1A1*3).57 Thesedifferencesmaydeterminedis-
tinct susceptibilities to nevirapine toxicity and also the tissue-
specific responses. While it is difficult to explain sex-related differ-
ences on the basis of genetic polymorphisms, as there is no evi-
dence for a sex-dependent pattern in the frequencies of
polymorphic SULTs, sex-dependent enzymatic regulation of
SULTs or differences in 3′-phosphoadenosine 5′-phosphosulphate
(PAPS) availability are plausible.
Little is knownabout the sexuallydimorphic expressionof SULTs
in humans, but sex-divergent SULTs are mostly female predomin-
ant in mice;58 for instance, female mice showed higher hepatic
mRNA levels of SULT1A1 comparedwithmalemice.58–60 Likewise,
higher expression of SULT1D1 was reported in the canine female
liver.61 In addition, a female predominance in SULT2A1/2A2 has
been reported in mice59,62 and rats.63,64 It is also noteworthy
that Alnouti and Klaassen58 demonstrated that androgens and a
male pattern of growth hormone secretion can have a suppressive
effect on the expression of some SULTs in mouse hepatic tissue,
while oestrogens and a female pattern of growth hormone secre-
tion can exert opposite effects. Furthermore, the activity of human
SULT2 enzymes, including SULT2B1b,which is expressed in the skin
and is capable of sulphonating a number of xenobiotics, has been
shown to undergo modulation by several types of nuclear recep-
tors; among these are peroxisomeproliferator-activated receptors
(PPARs).65 It has beenargued thatmetabolic interactions between
PPARg or PPARa and oestrogens, oestrogen receptors or oestrogen
receptor-related cofactors could explain, at least in part, somesex-
specific differences observed in PPAR-based treatments.66 Whet-
her or not a sexually dimorphic pattern in PPAR expression is an
underlying cause of differential nevirapine toxicity remains to be
established.
In addition to 12-hydroxy-nevirapine, current evidence sug-
gests that 3-hydroxy-nevirapine might also undergo bioactiva-
tion;26 however, there is no clear evidence so far associating
3-hydroxy-nevirapine or any 3-hydroxy-nevirapine derivative with
nevirapine-related toxic reactions. Interestingly, in the present
study, sex differences were found only for the plasma levels of
3-hydroxy-nevirapine and 12-hydroxy-nevirapine, which is con-
sistentwith thehypothesis of sex-dependent formationof reactive
metabolites. Also, the fact that women have lower UDP-
glucuronosyltransferase activity37,67 suggests that they may be
prone to less efficient detoxification of thesemetabolites thanmen.
Sex-dependent variations in theexpression/activityof PAPS syn-
thase enzymes, which catalyse the biosynthesis of the SULTcofac-
tor PAPS, may also contribute to the different toxicity outcomes.
PAPS is the universal donor of the sulphonyl moiety that enables
the sulpho-conjugation of SULTsubstrates. At least three PAPS syn-
thase isoforms (PAPSS1, PAPSS2a and PAPSS2b), with different ac-
tivities and tissue distributions, have been identified in humans.68
While PAPSS2b is the main isoform in human liver, PAPSS2a is not
expressed in this tissue and PAPSS1 is expressed to a lesser extent
inthe livercomparedwithseveralother tissues.68Asimilar tissuedis-
tribution of PAPS synthase isoforms has been reported inmice and,
interestingly, the hepatic expression of PAPSS2 in mice has been
found to be female predominant.59 Although sex-related differ-
ences in the expression of PAPS synthase enzymes do not appear
to have been investigated in humans, it is noteworthy that both
PAPSS1andPAPSS2arehighlypolymorphic69,70andaredifferentially
expressed in various tissues.71 In particular, PAPSS1 expression
is notably high in the skin,71 where sulphonation of 12-hydroxy-
nevirapinehasbeenassociatedwithnevirapine-inducedskin rash.32
It should also be noted that the role of immune-mediated
responses in the onset of nevirapine-related toxic reactions is
well recognized, with higher CD4+ cell counts being associated
with a higher risk of hepatotoxicity and skin rash.5,14 The predom-
inance of autoimmune diseases in women, who have stronger
humoral and cellular responses than men, is widely documen-
ted.72,73 While this is likely to contribute to the sex-dependent
profile of adverse events related to nevirapine treatment, current
therapeutic decisions already take some of these effects into
account. In fact, the introduction of lower CD4+ cut-off level cri-
teria for the initiation nevirapine therapy in women than in men
has led to a decreased incidence of drug-related toxicity.17 None-
theless, reports of adverse effects still persist, suggesting that
other factors are at play. Thus, in addition to distinct immune
responses, sex-related differences in metabolic activation may
contribute to the sexually dimorphic profile of adverse events
related to nevirapine treatment.
Nevirapine is among an increasing number of drugs found to
display sex differences in pharmacokinetics and in adverse
events upon biotransformation. Despite significant progress in
recent years, there are still large gaps in our knowledge of the
effects of sex upon the clinical pharmacokinetic of nevirapine.
Although our present work provides evidence for a sex-dependent
Sex differences in nevirapine pharmacokinetics
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dimorphism in nevirapine metabolism, it does not appear that
differences in the concentrations of nevirapine and its phase I
metabolites per se are the basis for the apparently higher risk of
idiosyncratic reactions to nevirapine in women. Future research
must be conducted to elucidate the role of SULTs in nevirapineme-
tabolism and bioactivation, and on the elicited sex-related differ-
ences in susceptibility to the toxicity of the drug, with a view to
the personalized, safer prescription of nevirapine.
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